Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-193,034
Closed -$873K 4640
2025
Q4
$873K Buy
193,034
+119,402
+162% +$612K ﹤0.01% 3019
2025
Q3
$397K Hold
73,632
﹤0.01% 3095
2025
Q2
$400K Sell
73,632
-138
-0.2% -$547 ﹤0.01% 2675
2025
Q1
$204K Sell
73,770
-40,915
-36% -$142K ﹤0.01% 2848
2024
Q4
$391K Buy
+114,685
New +$331K ﹤0.01% 2644
2022
Q4
Sell
-25,789
Closed -$203K 2846
2022
Q3
$203K Buy
+25,789
New +$301K ﹤0.01% 2099
2022
Q1
Sell
-26,645
Closed -$914K 3017
2021
Q4
$914K Buy
+26,645
New +$1.07M ﹤0.01% 2642
2020
Q4
Sell
-8,621
Closed -$401K 3402
2020
Q3
$401K Buy
+8,621
New +$481K ﹤0.01% 2394

John Overdeck's CVAC Position: Q1 2026 in Review

John Overdeck sold out of CureVac (CVAC) in Q1 2026, closing a stake of 193,034 shares — an estimated $873K sold.

John Overdeck first reported a position in CVAC in Q3 2020 and held it in 8 quarters. The position peaked at $914K in Q4 2021. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.

  • John Overdeck reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
  • John Overdeck sold 193,034 CureVac shares in Q1 2026, an estimated $873K.
  • John Overdeck first reported a position in CureVac in Q3 2020 and held it in 8 quarters.
  • John Overdeck's CureVac position peaked at $914K in Q4 2021.
  • 0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.